-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $68

Benzinga·10/13/2026 16:22:20
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $74 to $68.